Japan’s Tanabe Mitsubishi Files For Approval Of Canagliflozin
This article was originally published in PharmAsia News
Executive Summary
Tanabe Mitsubishi filed for the approval of its novel mechanism oral hypoglycemic SGLT2 inhibitor canagliflozin May 24.